CG Oncology (CGON) Long-Term Deferred Tax (2023)

CG Oncology's (CGON) quarterly Long-Term Deferred Tax came in at $4.7 million in Q4 2023.

CG Oncology (CGON) Long-Term Deferred Tax (2023) Analysis & Trends

CG Oncology (CGON) has 1 years of Long-Term Deferred Tax data on file, last reported at $4.7 million in Q4 2023.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $4.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.7 million (changed N/A YoY) and the FY2023 annual result came in at $4.7 million, changed N/A from the prior year.
Long-Term Deferred Tax was little changed at $4.7 million in Q4 2023.
In the past five years, Long-Term Deferred Tax ranged from a high of $4.7 million in Q4 2023 to a low of $4.7 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CG Oncology	6.63 Bn	6.63 Bn	-2.77 Mn

Download Data

Date	Value
Dec 31, 2023	4.67 Mn